Alvogen obtains European approvals forgeneric Gefitinib
Alvogen today announced that it has successfully concluded multiple registration applications for Gefitinibtablets. Alvogen received regulatory clearance for its product in several European countries and is among the first companies in Europe to obtain approval. Scientific approval has been obtained for Gefitinib 250 mg tablets.
Alvogen’s product is a fully generic and bioequivalent version of Iressa®* tablets and has been fully developed in-house. The drug is indicated for non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK. Gefitinib was developed by Lotus pharmaceuticals, an Alvogen affiliate and is part of a comprehensive portfolio of solid oral dosage oncology drugs being developed by Alvogen. Marketing authorizations have been filed by Alvogen and its partners in 24 European countrie.
•项目特色：欧洲上市产品,质量可靠.
项目联系人:王湧涛, 电话13675160533,邮箱: bd@huijucpu.com
往期精彩
汇聚南药牵线搭桥 校企携手共同探索人才培养新模式一一首届CRA人才培训班纪实